- Home
- PHAR vs DIAX Comparison
PHAR vs DIAX Comparison
Compare PHAR & DIAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- DIAX
- Stock Information
- Founded
- PHAR 1988
- DIAX 2005
- Country
- PHAR Netherlands
- DIAX United States
- Employees
- PHAR N/A
- DIAX N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- DIAX Finance Companies
- Sector
- PHAR Health Care
- DIAX Finance
- Exchange
- PHAR Nasdaq
- DIAX Nasdaq
- Market Cap
- PHAR 627.5M
- DIAX 557.9M
- IPO Year
- PHAR N/A
- DIAX N/A
- Fundamental
- Price
- PHAR $8.58
- DIAX $15.00
- Analyst Decision
- PHAR Strong Buy
- DIAX
- Analyst Count
- PHAR 3
- DIAX 0
- Target Price
- PHAR $27.00
- DIAX N/A
- AVG Volume (30 Days)
- PHAR 7.3K
- DIAX 96.6K
- Earning Date
- PHAR 10-24-2024
- DIAX 01-01-0001
- Dividend Yield
- PHAR N/A
- DIAX 7.93%
- EPS Growth
- PHAR N/A
- DIAX N/A
- EPS
- PHAR N/A
- DIAX N/A
- Revenue
- PHAR $285,745,000.00
- DIAX N/A
- Revenue This Year
- PHAR $20.89
- DIAX N/A
- Revenue Next Year
- PHAR $11.15
- DIAX N/A
- P/E Ratio
- PHAR N/A
- DIAX N/A
- Revenue Growth
- PHAR 30.64
- DIAX N/A
- 52 Week Low
- PHAR $6.65
- DIAX $12.80
- 52 Week High
- PHAR $13.20
- DIAX $15.12
- Technical
- Relative Strength Index (RSI)
- PHAR 53.32
- DIAX 39.87
- Support Level
- PHAR $8.71
- DIAX $14.93
- Resistance Level
- PHAR $9.59
- DIAX $15.84
- Average True Range (ATR)
- PHAR 0.33
- DIAX 0.14
- MACD
- PHAR 0.11
- DIAX -0.10
- Stochastic Oscillator
- PHAR 51.03
- DIAX 23.08
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.
About DIAX Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest
Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the Dow Jones Industrial Average by investing in an equity portfolio that seeks to substantially replicate the price movements of the DJIA, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio.